홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /반응

Diisopropylethylamine → 4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid-[(R)-1-(3,4-diethyl-benzyl)-2-oxo-2-(4-piperazin-1-yl-piperidin-1-yl)-ethyl]-amide

HRID 644320
노트
인쇄 미리보기

반응식

HRID 644320 반응식
[CH2:1]([C:3]1[CH:4]=[C:5]([CH2:11][C@@H:12]([NH:16][C:17]([N:19]2[CH2:24][CH2:23][CH:22]([N:25]3[CH2:31][CH2:30][C:29]4[CH:32]=[CH:33][CH:34]=[CH:35][C:28]=4[NH:27][C:26]3=[O:36])[CH2:21][CH2:20]2)=[O:18])[C:13](O)=[O:14])[CH:6]=[CH:7][C:8]=1[CH2:9][CH3:10])[CH3:2].CN(C(ON1N=NC2C=CC=CC1=2)=[N+](C)C)C.[B-](F)(F)(F)F.C(N(C(C)C)C(C)C)C.C([N:75]1[CH2:80][CH2:79][N:78]([CH:81]2[CH2:86][CH2:85][NH:84][CH2:83][CH2:82]2)[CH2:77][CH2:76]1)C1C=CC=CC=1>CCOC(C)=O.CN(C=O)C.C1COCC1>[CH2:1]([C:3]1[CH:4]=[C:5]([CH:6]=[CH:7][C:8]=1[CH2:9][CH3:10])[CH2:11][C@@H:12]([NH:16][C:17]([N:19]1[CH2:20][CH2:21][CH:22]([N:25]2[CH2:31][CH2:30][C:29]3[CH:32]=[CH:33][CH:34]=[CH:35][C:28]=3[NH:27][C:26]2=[O:36])[CH2:23][CH2:24]1)=[O:18])[C:13](=[O:14])[N:84]1[CH2:85][CH2:86][CH:81]([N:78]2[CH2:79][CH2:80][NH:75][CH2:76][CH2:77]2)[CH2:82][CH2:83]1)[CH3:2]
참가 물질실험 절차후처리출처 및 근거반응 노트

참가 물질

8

반응물 4

HCID 81531DiisopropylethylamineHCID 2733207O-(Benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium tetrafluoroborateHCID 36792751-Benzyl-4-piperidin-4-yl-piperazineHCID 68579001(R)-3-(3,4-diethyl-phenyl)-2-{[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyl]-amino}-propionic acid

생성물 1

HCID 59260968
4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carboxylic acid-[(R)-1-(3,4-diethyl-benzyl)-2-oxo-2-(4-piperazin-1-yl-piperidin-1-yl)-ethyl]-amide

시약·촉매·용매 3

HCID 6228Dimethylformamide용매HCID 8028Tetrahydrofuran용매HCID 8857Ethyl Acetate용매

실험 절차

A mixture of 500 mg (1.02 mmol) (R)-3-(3,4-diethyl-phenyl)-2-{[4-(2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl)-piperidine-1-carbonyl]-amino}-propionic acid, 320 mg (1.09 mmol) TBTU, 0.22 mL (0.97 mmol) ethyldiisopropylamine and 45 mL THF was stirred for 1 h at RT, then combined with 310 mg (1.20 mmol) 1-benzyl-4-piperidin-4-yl-piperazine and 5 mL DMF and stirred overnight. The reaction mixture was diluted by the addition of 30 mL EtOAc, extracted with 30 mL of a 15% K2CO3 solution and the organic phase was dried. The organic phase was evaporated down under reduced pressure and the residue purified by chromatography on silica gel. The intermediate product fractions were evaporated down under reduced pressure, the residue remaining (260 mg) was dissolved in 20 mL MeOH and hydrogenated in the autoclave in the presence of 50 mg Pd/C (10%) at 50° C. and 3 bar hydrogen pressure until the calculated volume of hydrogen had been taken up. The catalyst was filtered off, the solvent eliminated under reduced pressure and the residue purified by chromatography on silica gel. The product fractions were evaporated down under reduced pressure, the residue was triturated with diisopropylether, suction filtered and dried.

후처리

  1. stirringstirred overnight
  2. extractionextracted with 30 mL of a 15% K2CO3 solution
  3. customthe organic phase was dried
  4. customThe organic phase was evaporated down under reduced pressure
  5. customthe residue purified by chromatography on silica gel
  6. customThe intermediate product fractions were evaporated down under reduced pressure
  7. dissolutionwas dissolved in 20 mL MeOH and hydrogenated in the autoclave in the presence of 50 mg Pd/C (10%) at 50° C.
  8. filtrationThe catalyst was filtered off
  9. customthe residue purified by chromatography on silica gel
  10. customThe product fractions were evaporated down under reduced pressure
  11. customthe residue was triturated with diisopropylether, suction
  12. filtrationfiltered
  13. customdried

출처 및 근거

ORD 기록
ord-2fd646102c8b44f497e0d7077645feba
출처 데이터셋
uspto-grants-2010_04
DOI
10.6084/m9.figshare.5104873.v1
특허 번호
US07700589B2

반응 노트

불러오는 중…

이 페이지에서참가 물질실험 절차후처리출처 및 근거반응 노트